Anna Scavuzzo

Dr. Anna Scavuzzo

Urology, Instituto Nacional De Cancerología, Mexico City, Ciudad de México, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMaría D. Pérez-Montiel
María D. Pérez-Montiel
DCDennis Alexander Cerrato-Izaguirre
Dennis Alexander Cerrato-Izaguirre
YSYesennia Sánchez-Pérez
Yesennia Sánchez-Pérez
Jose Diaz-ChavezJose Diaz-Chavez
Jose Diaz-Chavez
Carlo C Cortes-GonzalezCarlo C Cortes-Gonzalez
Carlo C Cortes-Gonzalez
DPDiddier Giovanni Prada-Ortega
Diddier Giovanni Prada-Ortega
Bladder cancer (BC) is the most common neoplasm of the urinary tract, which originates in the epithelium that covers the inner surface of the bladder. The molecular BC profile has led to the development of different classifications of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). However, the genomic BC landscape profile of the Mexican population, including NMIBC and MIBC, is unknown. In this study, we aimed to identify somatic single nucleotide variants (SNVs) and copy number variations (CNVs) in Mexican patients with BC and their associations with clinical and pathological characteristics. We retrospectively evaluated 37 patients treated between 2012 and 2021 at the National Cancer Institute—Mexico (INCan). DNA samples were obtained from paraffin-embedded tumor tissues and exome sequenced. Strelka2 and Lancet packages were used to identify SNVs and insertions or deletions. FACETS was used to determine CNVs. We found a high frequency of mutations in TP53 and KMT2D, gains in 11q15.5 and 19p13.11-q12, and losses in 7q11.23. STAG2 mutations and 1q11.23 deletions were also associated with NMIBC and low histologic grade.

17 August 2014 in Case Reports in Urology
Verified
Journal Article
Open access
PDF file
Anna ScavuzzoAnna Scavuzzo
Anna Scavuzzo
ZRZael Arturo Santana Ríos
Zael Arturo Santana Ríos
NNNancy Reynoso Noverón
Nancy Reynoso Noverón
MRMiguel Angel Jimenez Ríos
Miguel Angel Jimenez Ríos
Growing teratoma syndrome (GTS) is a rare clinical entity, which presents with enlarging teratomas masses of the retroperitoneum or other locations, occurring during or after systemic chemotherapy for the treatment of nonseminomatous germ cell of the testis (NSGCT), with normalised tumour markers. Awareness of this syndrome is necessary in order to prevent unnecessary chemotherapy and allow optimal management. Prognosis is excellent after the excision of these tumors, but surgery has to be as complete as possible. Surgical resection of bulky GTS lesions is technically challenging; intraoperative complications may occur; that is, why the treatment must not be delayed. Our experience in the surgical management of these lesions is reviewed in the following work.

3 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Joel Vargas AhumadaJoel Vargas Ahumada
Joel Vargas Ahumada
Sofía Denisse González RuedaSofía Denisse González Rueda
Sofía Denisse González Rueda
Fabio Andrés SinisterraFabio Andrés Sinisterra
Fabio Andrés Sinisterra
QCQuetzali Pitalúa Cortés
Quetzali Pitalúa Cortés
LALiliana Patricia Torres agredo
Liliana Patricia Torres agredo
Francisco Osvaldo Garcia-PerezFrancisco Osvaldo Garcia-Perez
Francisco Osvaldo Garcia-Perez
Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated. 18F-FDG (fluorodeoxyglucose) PET/CT has numerous limitations in prostate cancer (PCa) and the utility in NEDPC has only been reported in a few series of cases. The objective of this study is to compare the lesions detection rate of the three radiotracers in metastatic t-NEPC patients. (1) Material and Methods: Retrospective evaluation of patients with prostate adenocarcinoma treated with androgen deprivation therapy, chemotherapy, a novel androgen receptor pathway inhibitor or a combination of them and a second tumour biopsy confirming t-NEPC was made. All patients underwent 18F PSMA-1007, 18F AlF-NOTA-Octreotide, and 18F-FDG PET/CT. Evaluation of positive lesions was determined and SUVmax of each radiotracer was estimated and correlated with computer tomography (CT) findings. (2) Results: A total of eight patients were included. The mean time from diagnosis of prostate adenocarcinoma to t-NEPC was 28.2 months, with a mean serum specific prostate antigen (PSA) of 16.6 ng/dl at the time of NEPC diagnosis. All patients were treated with antiandrogen therapy and 87.5% with chemotherapy. A total of 273 lesions were identified by CT from which 182 were detected by 18F-FDG PET/CT, 174 lesions by 18F PSMA-1007, and 59 by 18F AlF-NOTA-Octreotide. An interpatient analysis of the lesions was performed and dual tracer 18F-FDG PET/CT and 18F PSMA-1007 PET/CT detected a total of 270/273 lesions (98.9%). (3) Conclusions: NEDPC patients demonstrated wide inter and intrapatient molecular imaging heterogeneity within the three radiotracers. 18F-FDG detected most lesions in t-NEPC among all radiotracers, especially in visceral sites; 18F PSMA-1007 detected more bone lesions. 18F AlF-NOTA-Octreotide showed no significant utility.

13 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Joel Vargas AhumadaJoel Vargas Ahumada
Joel Vargas Ahumada
Sofía Denisse González RuedaSofía Denisse González Rueda
Sofía Denisse González Rueda
Fabio Andrés SinisterraFabio Andrés Sinisterra
Fabio Andrés Sinisterra
Pamela Casanova-TriviñoPamela Casanova-Triviño
Pamela Casanova-Triviño
QPQuetzali Pitalúa-Cortés
Quetzali Pitalúa-Cortés
Francisco Osvaldo Garcia-PerezFrancisco Osvaldo Garcia-Perez
Francisco Osvaldo Garcia-Perez
Prostate cancer is a leading cause of cancer death in men worldwide. Imaging plays a key role in disease detection and initial staging. Emerging data has shown the superiority of PSMA imaging with PET/CT over conventional imaging for primary diagnoses. Single photon emission computed tomography is more available worldwide, and the imaging agent is low in cost. The aim of this study is to compare the diagnostic accuracy of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT to 18F-PSMA-1007 PET/CT in the primary diagnosis of prostate cancer and the impact on clinical staging. Methods: In this prospective controlled study, 18 patients with histologically confirmed prostate cancer with unfavorable intermediate-, high-, and very high-risk characteristics were recruited to undergo 18F-PSMA-PET/CT and 99mTc-iPSMA SPECT/CT. The median age of the patients was 71 years old, and the median PSA level was 23.3 ng/mL. Lesions were divided into the prostate, seminal vesicles, lymph nodes, bone, and visceral metastases. Volumetric analysis was also performed between the two imaging modalities and correlated with PSA levels. Results: A total of 257 lesions were detected on 18F-PSMA-PET/CT: prostate (n = 18), seminal vesicles (n = 12), locoregional lymph nodes (n = 62), non-locoregional (n = 67), bone (n = 90), and visceral (n = 8). Of these, 99mTc-iPSMA-SPECT/CT detected 229 lesions, while both reviewers detected 100% of the lesions in the prostate (18/18), seminal vesicles (12/12), and visceral (8/8); LN LR (56/62; 90%), NLR (57/67; 85%), and bone (78/90; 86%). There were no statistically significant differences between volumetric parameters (t = −0.02122; p = 0.491596). Conclusions: 99mTc-iPSMA SPECT/CT is useful in the primary diagnosis of prostate cancer. Despite it showing a slightly lower lesion detection rate compared to 18F-PSMA PET/CT, it exhibited no impact on clinical staging and, consequently, the initial treatment intention.

1 July 2017 in Urology Case Reports
Verified
Journal Article
Open access
Anna ScavuzzoAnna Scavuzzo
Anna Scavuzzo
ZRZael Santana Rios
Zael Santana Rios
CDCristobal Diaz-Gomez
Cristobal Diaz-Gomez
BGBeatriz Varguez Gonzalez
Beatriz Varguez Gonzalez
VOVictor Osornio-Sanchez
Victor Osornio-Sanchez
MJMiguel Angel Jimenez-Rios
Miguel Angel Jimenez-Rios
To our knowledge, this is the first reported case of renal cell carcinoma in kidney horseshoe diagnosed in the second trimester of pregnancy. We performed open radical nephrectomy when the pregnancy was completed. Kidney cancer is rare during pregnancy and the symptoms can be mimic urinary infection. The diagnosis and its management can be a challenge.

20 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RGRodrigo González-Barrios
Rodrigo González-Barrios
NANicolás Alcaraz
Nicolás Alcaraz
MMMichel Montalvo-Casimiro
Michel Montalvo-Casimiro
ACAlejandra Cervera
Alejandra Cervera
CACristian Arriaga
Cristian Arriaga
LHLuis A. Herrera
Luis A. Herrera
Despite having a favorable response to platinum-based chemotherapies, ~15% of Testicular Germ-Cell Tumor (TGCT) patients are platinum-resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarray-based comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum-sensitive and 14 were platinum-resistant. We incorporated analyses of mutational burden, driver mutations, and SNV and CNV signatures. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplifications on segment 2q11.1 as a novel variant with chemosensitivity biomarker potential. Our data shed light into understanding platinum resistance in a Latin-origin population.